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Abstract The use of immature oocytes subjected to in vitro
maturation (IVM) opens interesting perspectives for fertility
preservation where ovarian reserves are damaged by patholo-
gies or therapies, as in PCO/PCOS and cancer patients.
Human oocyte cryopreservation may offer some advantages
compared to embryo freezing, such as fertility preservation in
women at risk of losing fertility due to oncological treatment
or chronic disease, egg donation and postponing childbirth. It
also eliminates religious and/or other ethical, legal, and moral
concerns of embryo freezing. In addition, a successful oocyte
cryopreservation program could eliminate the need for donor
and recipient menstrual cycle synchronization. Recent ad-
vances in vitrification technology have markedly improved
the oocyte survival rate after warming, with fertilization and
implantation rates comparable with those of fresh oocytes.
Healthy live births can be achieved from the combination of
IVM and vitrification, even if vitrification of in vivo matured
oocytes is still more effective. Recently, attention is given to
highlight whether vitrification procedures are more successful
when performed before or after IVM, on immature GV-stage
oocytes, or on in vitro matured MII-stage oocytes. In this
review, we emphasize that, even if there are no differences
in survival rates between oocytes vitrified prior to or post-
IVM, reduced maturation rates of immature oocytes vitrified
prior to IVM can be, at least in part, explained by underly-
ing ultrastructural and biomolecular alterations.
Keywords Oocyte . Vitrification . In vitro maturation .
Ultrastructure . Transmission electronmicroscopy
Clinical IVM
Since its introduction in the 1990s, in vitro maturation (IVM)
has emerged as an attractive infertility treatment option. Early
experience with IVM yielded limited success in humans and
satisfactory pregnancy rates were obtained when advances in
IVM protocols were especially associated to stricter patient
selection and alternative strategies, such transfer frozen re-
placement cycles of embryos derived from IVM oocytes [1,
2]. IVM has the potential to substitute for, or be an adjuvant to,
standard in vitro fertilization (IVF) protocols for several rea-
sons. It requires no or very little gonadotropin supplementa-
tion in vivo and it has been proposed as an alternative assisted
reproduction approach to reduce drawbacks of controlled
ovarian induction (COI) [2]. The most appropriate candidates
for IVM are polycystic ovaries (PCO) and polycystic ovarian
syndrome (PCOS) patients. By not using COI, the risk of
ovarian hyperstimulation syndrome (OHSS) is diminished
[3]. Along with the decreased risk of OHSS, reduction of cost
per cycle, drug-related side effects and psychological stress
are advantages of IVM protocol.
Antral follicle count (AFC) is important in selection for
IVM in normo-ovulatory patients. If the number of follicles
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available for recovery is too low, the cycle outcome would be
unsatisfactory. The parameters for selection of IVM candi-
dates are: age ≤ 36 years, body mass index < 30 kg/m2, FSH
< 10 mIU/mL, estradiol < 250 pmol/mL, AFC > 5, and
antimüllerian hormone (AMH) > 1.3 ng/mL [4]. Initial work
with clinical IVMwas in the 1960s by Edwards [5]; others [6]
reported the first baby using immature oocytes collected from
unstimulated cycles in a donor oocyte program. While,
Trounson et al. [1] reported the first birth from PCOS patients
using the mother’s own oocytes in 1994. The first IVM at-
tempts using oocytes collected from unstimulated ovaries date
to the 1990s, but a systematic development of IVM occurred
in the second half of same decade [2]. In IVM cycles, preg-
nancy rates are unsatisfactory when compared with IVF cy-
cles, but patient selection can improve IVM outcomes.
Several studies have reported the obstetric and perinatal out-
comes and incidence of congenital malformation after IVM
[2, 3]. Even if indications for IVM have expanded—including
both normal and poor responders—limitations of IVM as an
approach for fertility preservation include the low number of
patients eligible (PCO/PCOS are only the 5–7% of the entire
IVF patient population and few are the cancer patients who
cannot undergo hormonal stimulation with high peak estradiol
concentrations) and low maturation rates of GVoocytes (50–
55% at best).
Oocyte vitrification technology
Although early successes were reported using human cryopre-
served oocytes, this technology was widely perceived to be
inefficient and subjected to concerns on safety until many of
these worries were alleviated by fundamental validation stud-
ies in the 1990s. This led to the adoption of oocyte cryopres-
ervation as a clinical tool, particularly in Italy, where pending
legislative changes sought to outlaw embryo cryopreserva-
tion. Oocytes can also be cryopreserved by non-equilibrium
procedures, such as vitrification, rapid cooling, and ultrarapid
cooling [7]. Vitrification is an alternative approach to embryo/
oocyte cryopreservation, which was described as a revolution-
ary technique. It is different from slow freezing in that it
avoids the formation of ice crystals in the intracellular and
extracellular spaces [8]. It is the solidification of a solution
by an extreme elevation in viscosity at low temperatures with-
out ice crystal formation, a process achieved by a combination
of a high concentration of cryoprotective additives (CPAs) (4–
8 mol/L) and an extremely high cooling rate [9, 10]. The
common freezing solutions used for vitrification are com-
posed of permeating (e.g., EG, G, DMSO, PG, acetamide;
> 4 M) and non-permeating (e.g., sucrose, trehalose;
> 0.5 M) agents [9]. The major drawback of the vitrification
procedure is the cytoxicity connected to the high concentra-
tion of CPAs, making important the temperature control and a
consciousness in the use of CPA cocktails [11]. Evidences on
CPA cytotoxicity were strengthened by a report using Raman
microspectroscopy, demonstrating an altered protein distribu-
tion of the oocyte cortex and a severe disruption of the cortical
F-actin network after exposure of ovine oocytes to DMSO and
EG [12]. Recently, the application of strategies to reduce CPA
concentrations ranged from the increase in the vitrification
medium viscosity, by macromolecular supplementation [7,
13], to the use of microdevices allowing to reduce the time
available for ice nucleation and growth [14]. To further in-
crease the cooling rate (> 10.000 °C/min) necessary for suc-
cessful vitrification, the volume of the solution in which the
oocytes are vitrified has been dramatically decreased (0.1–
2 µL). To achieve this, special carrier systems (open and
closed devices) were developed, such as open pulled straws,
Flexipet-denuding pipettes, Cryotop, electron microscopy
grids, cryoloops, or BHemi-Straw^ system. Up to now, the
debate on open vs closed device is still opened and connected
to the risk of cross-contamination as well as to clinical out-
comes. The risk of contamination in open and closed vitrifi-
cation devices was studied by evaluating the sterility condi-
tions of the liquid nitrogen (LN), where contaminants of bac-
terial origin were found in the cryostorage containers both
before and after their filling with LN [15]. However, proce-
dures for decontamination, especially for open carriers, have
been successfully produced [16]. Recent data from prospec-
tive studies are evidencing comparable maturation rates, fer-
tilization rates, embryo developmental competence, clinical
pregnancy, and live birth rates between the open and closed
systems [17–20]. Comparing the open and closed systems,
acceptable survival rates were reported for both [21].
Vitrification may be difficult to perform, because of the
very concentrated and viscous volume of vitrification solu-
tions in which the oocytes must be handled for a very limited
amount of time (< 1 min) prior to and during vitrification.
Similar to slow freezing, rapid warming is required for the
optimal survival of vitrified oocytes.
Based on the current state of evidences, modern procedures
to cryopreserve oocytes should no longer be considered ex-
perimental as declared in 2013 by the American Society for
Reproductive Medicine (ASRM) and the Society for Assisted
Reproductive Technology (SART). In fact, Cobo et al. [22]
stated their findings from a randomized controlled trial of over
3000 fresh and 3000 vitrified oocytes (92.5% survival) in an
oocyte donation program, confirming no detrimental effects of
vitrification on subsequent development or implantation.
Others, using the same vitrification protocols, also reported
similar outcomes in oocyte donation programs [23]. Results
obtained with the same technique in infertility program
showed a trend towards lower clinical outcomes from vitrified
oocytes, especially over the age of 34 [24]. With improving
the results, application of vitrification for human oocyte cryo-
preservation is increasing but the number of oocytes necessary
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to achieve reasonable success should also take into account
the patient’s age [25].
Vitrification and oocyte quality
Vitrification was developed as the promising technology to
capitalize the reproductive potential of surplus oocytes and
preserve fertility, even if slow freezing remains a suitable
choice [26]. Starting from the assumption that clinical data tell
that oocyte cryopreservation at the mature stage is a safe and
efficient procedure, criteria to assess oocyte quality after
warming are not yet standardized [27].
Recent advances in live cell imaging are becoming valu-
able tools to assess alterations in ooplasmic compartments.
Intracellular calcium concentrations, indicators of cellular
damage, have been determined on fresh, thawed, and warmed
human oocytes, evidencing a better preservation of calcium
dynamics in oocytes subjected to a close vitrification system
than slow freezing [28]. However, following calcium tran-
sients for 16 h after fertilization by ICSI, warmed human
MII-stage oocytes showed calcium transients occurring over
a longer period of time, with a higher amplitude and a lower
frequency, respect to the in vivo counterpart [29]. Outcomes
of this study were not reported because calcium-sensitive fluo-
rescent dyes and the high-intensity excitation light may impair
embryo development [29]. Therefore, this method does not
allow use of the same oocyte to follow the further embryonic
development but can provide important data on the metabolic
status of warmed oocytes. Interestingly, kinetics of embryos
obtained from ICSI of vitrified/warmed human oocytes evi-
denced that oocyte vitrification has no consequence on the
completion of oocyte meiosis, but affects the fertilization pro-
cess and embryo kinetics at the zygote stage, thus evidencing
that the detrimental effects of vitrification are probably con-
nected to a pronuclei instability [30]. Variation in clustering
and distribution of mitochondria can reflect developmental
competence [31].Mitochondrion selective probes can, indeed,
be used to analyze mitochondrial patterns or variations in the
mitochondrial membrane potential in vitrified/warmed oo-
cytes. Decreased inner membrane potential was found in hu-
man oocytes vitrified after IVM, indicating damage of the
mitochondrial functions [32]. However, the reduction in the
ΔΨm seemed to spontaneously recover after 4 h in culture to
levels of fresh oocytes [33]. Microfilaments can also be indi-
cators of cryodamage, as reported by [34], where microfila-
ment structure was altered in vitrified human oocytes and did
not restore to the physiological configuration before than 3 h
after thawing. Precocious cell cycle entry, abnormal chromatin
configurations, and disruption of the actin cytoskeleton were
observed in vitrified-warmed cumulus-enclosed GV-stage rat
oocytes [35].
Oocyte in vitro maturation prior to and
post-vitrification
In ART, 15–20% of the oocytes retrieved from patients is
meiotically immature, even after controlled hormonal hyper-
stimulation (COI) [36, 37]. Since there is the possibility of an
abnormal embryonic development and defective cytoplasmic
maturation, these so called Bleftover^ oocytes are usually
discarded because of their poor-quality. However, due to the
not enough number of mature oocytes retrieved from the pa-
tients who are low responders or having an unsynchronized
cohort of follicles, immature oocytes can increase the yield of
total available oocytes. At the same time, cryopreservation of
in vitro matured oocytes could meet the demand of patients
who want to preserve fertility in case of pathologies or thera-
pies damaging ovarian reserves [38]. Oocyte storage may also
circumvent the ethical and legal problems encountered in em-
bryo cryopreservation [39]. Apart from the debate about the
definition and clinical outcome of IVM [40–42], the recent
issue on performing IVM before or after vitrification is pro-
ducing interesting data.
Although nowadays comparable high survival rates (80–
85%) have been reported for oocytes vitrified prior to or post-
IVM [43, 44], differences found in terms of cellular alterations
and clinical outcomes claim for an impairment in the ability of
human IVM oocytes to mature, fertilize, and cleave, that
seems to be dependent on the stage in which vitrification
occurs.
In early studies [45], the survival of GVoocytes was equiv-
alent to that of mature oocytes (30%) following cryopreserva-
tion. However, only 20% of the surviving GV oocytes
underwent subsequent maturation. The first baby from a vit-
rified IVM oocyte was reported in 2009 [46]. In this case, 89%
of the oocytes extruded a polar body, 25% survived, 75%
fertilized, and a singleton pregnancy was achieved. Several
studies have undertaken comparison of freezing at either the
immature stage or MII following IVM [47–50]. Cao et al.
(2009) reported that maturation rates of GVoocytes after vit-
rification were significantly lower with respect to those of GV
oocytes subjected to IVM and then vitrified at the MII stage
(50.8 vs 70.4%, respectively) [47], thus suggesting a reduced
oocyte maturation potential by vitrification at immature stage
[48]. Our previous studies showed that almost 90% of imma-
ture oocytes survived after vitrification and IVM. However,
even if oocyte morphology and zona pellucida birefringence
were not altered [51, 52], the maturation potential was reduced
by Cryotop vitrification of human immature GV-stage oo-
cytes, as seen by reduced maturation rate and oocyte viability
respect to the fresh counterpart [36, 53]. Superior maturation
rates of GVand MI oocytes vitrified post-IVM (≈ 64%), have
been demonstrated in terms of mitochondria, chromatin, and
spindle formation, respect to those vitrified prior to IVM
(≈ 33%) [44]. Moreover, no detrimental effects were seen on
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the meiotic spindle configuration between oocytes matured
in vitro and those vitrified after IVM [32]. Differently, others
stated that cryopreserving MII oocytes post-IVM is more ef-
ficient than at the immature stage pre-IVM [38]. In a recent
report, several outcomes—ranging from survival to develop-
ment to blastocyst rates—were higher in GV-stage oocytes
vitrified at GVand then matured in vitro up to the MII-stage,
with respect to those vitrified post-IVM [54]. However, oo-
cytes matured in vitro from unstimulated ovaries and vitrified
post-IVM, displayed reduced developmental potential, as in-
dicated by only the 5.6% of the resulting embryos able to
reach the blastocyst rate [55]. Data available in literature about
vitrification prior or post-IVM are summarized in Table 1.
It is of note that the birth of a healthy child has been suc-
cessfully obtained after the implantation of vitrified/warmed
embryos obtained by IVM in a PCOS patient [57].
The pool of immature oocytes can also represent another
option for cancer patients, reinforcing the need of clarification
on the right timing for vitrification and IVM. In a retrospective
analysis about immature oocytes retrieved from excised ovar-
ian tissues, matured in vitro and then vitrified, the mean mat-
uration rate following IVM was of the 79% [58]. In another
study, immature oocytes from ovariectomy specimens and
vitrified post-IVM, produced a 65% fertilization rate and one
clinical pregnancy [59]. Lower overall maturation rates (30%)
were obtained by immature human oocytes retrieved from
discarded ovarian medulla tissues and subjected first to IVM
and then to vitrification, but the post-warming survival rate
was of the 64% [60]. If IVMwas performed after IVM onMI-
stage oocytes from cancer patients, maturation rates were sig-
nificantly lower than those obtained after COI (39.1 vs 85.2%)
[61]. The combination of IVM and vitrification on immature
oocytes might, indeed, represent a complementary strategy for
fertility preservation for those cancer patients where hyper-
stimulation cannot be applied.
Ultrastructure of oocytes vitrified prior to or
post-IVM
Transmission electron microscopy (TEM) evaluation, alone or
integrated with immunocytochemical approach, is especially ef-
fective in estimating how cooling rates and cryoprotectants affect
the oocyte structural integrity [62]. However, even if TEM en-
ables the best exploration of the cell ultrastructure, important lim-
itations—such as relying on expensive technology, highly trained
personnel, lengthy specimen preparation, and observation—make
it hardly usable for the analysis of large numbers of samples.
The impact of vitrification on the oocyte fine morphology
was investigated in different mammals and at different stages.
However, results are yet inconclusive, with species-specific
differences and, among the same species, confounding results
can be obtained by the availability of different protocols and/
or devices for vitrification.
Up to now, ultrastructural data mainly showed alterations
to microvilli, mitochondria, lipid droplets, and cortical gran-
ules (CG) after vitrification [63–66].
However, available literature did not yet unravel which is,
between immature and mature oocytes, the optimal maturation
stage for vitrification. In porcine cumulus-oocyte-complexes
(COCs), ultrastructural alterations were found after vitrification,
butmore severe at GV-stage, as seen by the separation of cumulus
cell from the oocytes, fractured zona pellucida, interrupted gap
junctions, reduced microvilli, and mitochondrial matrix density
[63]. If vitrification occurred at the MII-stage, the morphology
ofmitochondria appeared normal, with cortical granules still lined
under the oolemma and many vacuoles in the cytoplasm. Given
the temperature-sensitive nature of the MII spindles, cryopreser-
vation of immature stages may offer a theoretical advantage, due
to the absence of the meiotic spindle and the presence of the
nucleus. However, the percentage of oocytes with normal spindle
organization decreased significantly in both GV- and MII-stage
oocytes [63]. In bovine, data are controversial with a study
reporting that oocytes vitrified at the GV-stage were more suscep-
tible to ultrastructural modifications, including a significant pre-
mature CG exocytosis [64] and another in which the degree of
cytoplasmic degenerations increased with the timing of vitrifica-
tion, being more evident at MII-stage oocytes [65]. Specifically,
from a marked reduction in the number of cortical granules,
changes in the cytoplasmic density at the periphery, the beginning
of the vacuolization process and mitochondrial clamping ob-
served at GV-stage ultrastructural damages increased at the MII-
stage with severe vacuolization, an irregular shape throughout the
ooplasm, an almost complete lack of cortical granules and drastic
mitochondrial degenerations indicating cell death [65]. In canine,
even if no significant differences were found in the rates of GV
oocytes reaching the MII-stage, vitrified/warmed immature oo-
cytes showed important ultrastructural alterations [66].
Also in humans, comprehensive ultrastructural studies on
vitrified/warmed oocytes, especially highlighting differences
between the pre- and post-IVM vitrification, are scarce and
conclusive evidences to identify top-quality cryopreserved oo-
cytes were only recently generated.
Vitrification/warming seems to not significantly impair hu-
man oocyte general microarchitecture. In fact, dimensions and
density of the ooplasm by light microscopy (LM) examination
of semithin sections was comparable to the fresh counterpart
[21, 52, 67–69] (Fig. 1). However, human oocytes subjected
to vitrification showed peculiar and stage-specific signs of
ultrastructural alterations.
Vitrified/warmed immature GV-stage human oocytes
A percentage of vitrified/warmed immature GV-stage oocytes
showed, in fact, short and small microvilli irregularly
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distributed on the ooplasm and small vacuoles, occasionally
large and isolated, abnormally located in the oocyte periphery.
Noteworthy, important subcellular compartments such as cor-
tical granules, SER, mitochondria, and nucleus did not show
evident damages after warming [68].
In vitro matured metaphase II-stage oocytes
from vitrified/warmed GV
When oocytes were vitrified at the GV-stage and then subject-
ed to IVM, a series of alterations occurred in their cytoplasm.
Part of these alterations, such as the presence of numerous,
uniformly distributed, very large MV complexes (Fig. 2a, b)
and of occasional, still migrating CGs in the deep cytoplasm
(Fig. 2b), were also found in fresh IVM oocytes [70] and are
presumably related to the prolonged culture (the former) or to
an incomplete maturation (the latter).
Other alterations, such as various degrees of vacuolization
(Fig. 2c) and the presence of a reduced amount of CGs (Fig.
2d), including the presence of isolated elements in the inner
cytoplasm [71], may be due to the superimposition of a pos-
sible cryodamage [52]. The reduced number of CG, irrespec-
tive of the device used for vitrification (open or closed) (Fig.
3), is sometimes due to a premature exocytosis of the CG
content into the perivitelline space (PVS), resulting in ZP
hardening [26]. A compaction of the inner aspect of the ZP,
with the loss of its typical filamentous texture, due to the
presence of large areas of filaments packed together, was
sometimes found in the same samples (Fig. 2a) [26].
Spindles and chromosomes showed a significantly higher ab-
normal configuration, with respect to MII-stage oocytes ma-
tured in vivo or in vitro [56].
Vitrified/warmed mature MII-stage human oocytes
Ultrastructural changes detected after vitrification/warming on
MII-stage human oocytes mainly involved microvilli, vacu-
oles, smooth endoplasmic reticulum, mitochondria, and corti-
cal granules. Normally, after warming, numerous long and
thin microvilli projected into a PVS with regular shape, width,
and content (Fig. 3) [52, 67, 68], but in about the 30% of
warmed oocytes, focal surface areas with rare and/or short
microvilli were found [67, 68].
The occurrence of vacuolization seemed to be cryodevice-
related, since a slighter degree was detected in human MII-
stage oocytes vitrified by open carrier devices [21, 68]
(Figs. 1b and 3b), with respect to closed ones [28, 69] (Fig.
1c). Regardless of their numbers, ultrastructural characteristics
of vacuoles were the same: they appeared as empty structures,
irregularly rounded and bordered by a membrane, often
interrupted and in association with multivesicular bodies
(MVBs) and lysosomes (Fig. 4) [26].
Human oocytes after vitrification frequently showed typi-
cal M-SER aggregates, similar for dimensions, shape, and
Fig. 1 Fresh control (a) and
vitrified-warmed (b, c) human
oocytes. LM shows the general
morphology and organelle
microtopography. No explicit
differences in shape, dimensions,
and organelle distribution were
found between fresh and vitrified
oocytes. Apparent variations of
ZP thickness is an effect of the
section plane (not equatorial).
Vacuoles were detected only
sporadically in both fresh (a) and
vitrified-warmed (b, c) oocytes.O
oocyte, Va vacuoles, ZP zona
pellucida, M-SER mitochondria-
smooth endoplasmic reticulum
aggregates, PB polar body
(modified from: [69] Bianchi
et al., 2014 (a, c) and [67] Nottola
et al., 2009 (b))
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location to those observed in fresh controls (Fig. 5a, b).
However, in a percentage of vitrified-warmed oocytes, small
and slender, immature M-SER aggregates could be found
(Fig. 5c) [67].
Ultrastructural data available up to now seems, therefore, to
underline that vitrification prior to IVM could be beneficial for
the absence of the cryosensitive meiotic spindle and the pres-
ence of a compact nucleus protecting the genetic material.
However, the reduction in the exchange surface between
vitrified/warmed GV-stage human oocyte and corona radiata
cells, deducible from the shortness and reduction of microvilli
[69], could affect the subsequent IVM.
Mature MII-stage human oocytes vitrified/warmed post
to IVM
In oocytes subjected to vitrification post-IVM, general fea-
tures were physiologically preserved, with an abundant pres-
ence of mitochondria often associated to SER, to formM-SER
aggregates, and less frequently to vesicles, to form MV com-
plexes. The number of mitochondria was slightly, but not sta-
tistically, higher, respect to oocytes vitrified prior to IVM [71].
From the same study, it seems that oocytes cryopreserved after
IVM show slight improvements in term of ultrastructural
characteristics of cytoplasm maturation in respect to those
vitrified before IVM [71].
Somatic compartments in IVM and vitrification
Cumulus and granulosa cells attracted the attention of re-
searchers and clinical practitioners to unravel their role as
protectors against vitrification-induced damage or as vulnera-
ble to cryoinjuries. MII-stage human oocytes vitrified with or
without corona radiata did not show differences in zona pel-
lucida hardening and number of cortical granules but, after
conventional IVF insemination, oocytes with an intact corona
radiata had higher fertilization rates [73]. Human MII-stage
COCs subjected to in vitro aging, evidenced a re-compaction
of the CC cells combined with the loss of the elongated shape
of the corona cells after in vitro culture, irrespective of the age
of the patients [74]. Differently, meiotic spindle seemed to
better recover after vitrification without cumulus cells, as seen
by a significantly higher percentage of detectable spindle in
human denuded MII oocytes [75]. The protective effects of
corona radiata/cumulus cells during vitrification/warming was
studied on equine COCs. Detrimental effects of CPAs on de-
nuded GV-stage oocytes to reach MII-stage with a normal
spindle were overcome in COCs by the presence of corona
Fig. 2 Ultrastructure of human
MII stage oocytes obtained from
IVM of vitrified-warmed GV-
stage oocytes. Mitochondria are
generally rounded and provided
with few peripheral or transverse
cristae. Note the presence of
complexes between mitochondria
and vesicles of smooth
endoplasmic reticulum (a, b).
Dumbbell-shaped, possibly
dividing mitochondria can be
occasionally found in the ooplasm
(asterisk in d). Extensive
vacuolization is showed in c.
Cortical granules are sparse in the
ooplam (b) and form a
discontinuous layer beneath the
oolemma in vitrified-warmed
oocytes (a, d). Microvilli are seen
on the oolemma of vitrified-
warmed oocytes (b, c). ZP zona
pellucida, m mitochondria, mv
microvilli, MV mitochondria-
vesicle complexes, Ly lysosome,
V vacuoles, CG cortical granules
(modified from: [52] Shahedi
et al., 2013)
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radiata/cumulus cells, probably protecting the oocyte against
disruption of cytoplasmic factors important to meiotic spindle
reassembly [76]. However, vitrified/warmed cumulus-
enclosed GV-stage oocytes showed damages to tranzonal pro-
jections and microtubules in rhesus monkey [77], and the loss
of transzonal projections in vitrified/warmed mouse oocytes
from pre-antral follicles [78], showing how oocyte-cumulus
cell contact and interactions, particularly strict at the GV-
stage, are sensitive to cryopreservation.
Deleterious effects of vitrification, such as retraction of
cumulus cell projections, were observed in vitrified sheep
COCs [79], similar to immature vitrified COCs from primed
rats, were a reduction of F-actin in ooplasm and oocyte cortex
was associated to irreversible but irregular retraction of
transzonal projections [35]. Themechanical removal of cumu-
lus cells from immature bovine oocytes did not affect their
maturation competence but reduced blastocyst rates, when
compared with intact COCs [80]. Bovine oocytes subjected
to IVM only, showed a different distribution of membrane-
bound vesicles and lipid droplets between MII-stage denuded
oocytes (DOs) and cumulus-enclosed oocytes (CEOs), asso-
ciated to a significant reduction in total lipid level in DOs and
to a differential expression of genes regulating energy metab-
olism, transcription and translation between CEO and DO
[81]. Vitrification of GV-stage bovine COCs prior to IVM
allowed more than 30% of blastocyst yields if cumulus cell
layers were downsized, whereas only 13.4 and 23.7% of the
matured oocytes deriving from denuded oocytes and full-size
COCs reached the blastocyst stage, respectively [82].
Molecular integrity of IVM oocytes and vitrification
Among the genes expressed in germ cells, ZAR1, BMP15,
GDF9, and NLRP5 transcripts were detected at high levels
in the oocytes, as oocyte-specific markers [83]. ZAR1 was
shown to be critical for early-phase embryo development.
Importantly, knockout of this gene makes embryos incapable
of developing beyond the first cleavage stage [84]. Also,
NLRP5 is a maternal effect gene required for the development
prior to the zygotic genome activation [85]. The NLRP5 tran-
script was detected during oocyte growth from primary folli-
cles, and its level decreases post fertilization [86]. In addition,
both BMP15 and GDF9 as germ cell-specific genes affect
growth and function of oocytes [87].
Human IVM oocytes retrieved from unstimulated or hor-
monally stimulated cycles have a higher incidence of spindle
defects and chromosomal misalignments compared with the
in vivo matured oocytes [88, 89], as also demonstrated by
ultrastructural study in animal models [90]. It was reported
that IVM oocytes have a high incidence of aneuploidy [91]
and the generated embryos are with high rate of fragmenta-
tion, deformity in blastomeres nucleation, and aneuploidy
[92]. These phenomena indicate a failure in the cell cycle
regulation, and many of the genes participating in this process
were expressed in oocytes undergoing IVM [93].
Oocyte degeneration can be alleviated using vitrification
technology. However, different factors of high cryoprotectant
concentrations, cooling, and osmotic stress may initiate the
Fig. 3 Fresh (a) and vitrified-warmed MII oocytes (b, c). TEM
micrograph showing the presence of a continuous layer of cortical
granules under the oolemmal membrane (a), differently to vitrified-
warmed oocytes, irrespective of the open (b) or closed (c) cryodevices
used. Note the increased compaction of the inner aspect of the ZP in b in
comparison with the looser texture in a, c. CG cortical granules, ZP zona
pellucida, PVS perivitelline space, mvmicrovilli, V vacuole, SER smooth
endoplasmic reticulum (modified from: [67] Nottola et al., 2009 (a, b);
[69] Bianchi et al., 2014 (c))
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apoptosis within MII oocytes, probably related to the activa-
tion of receptor- and mitochondria-mediated apoptotic path-
ways [94, 95]. However, inclusion of apoptosis inhibitors in
the incubation medium after warming, improved the in vitro
developmental ability of vitrified oocytes by increasing mito-
chondrial function, reducing apoptotic level and changing
apoptosis-elated gene expression [96, 97]. Therefore, assess-
ment of apoptosis genes expression is an efficient tool for
assessing oocytes viability after vitrification. Bcl-2 family is
apoptosis regulator, which control the permeabilization of the
mitochondrial outer membrane; and are either pro-apoptotic
such as Bax and BAD, or anti-apoptotic including Bcl-2 and
Bcl-xL. In 2007, Dhali and associates showed that there is a
correlation between the compromised development compe-
tency and alteration in expression level of Bax, Bcl2, and
p53 genes in the vitrified embryos [97]. Cumulus cells also
have a critical role in protecting oocyte against oxidative stress
[98]. In this regard, Turathum et al. [66] reported that the
expression levels of HSP70, Dnmt1 and SOD1 genes in con-
trol and vitrified-warmed canine oocytes with cumulus cells
was comparable. Vitrification can also influence the epigenet-
ic makeup of oocytes. It induced changes in histone H4 acet-
ylation and histone H3 lysine 9 methylation in oocytes of pigs
[99]. Additionally, vitrification significantly decreased the ex-
pression of Dnmt1 messenger RNA (mRNA) in mouse MII
oocytes [100, 101]. However, in the absence of cryopreserva-
tion, the process of IVMmay induce degeneration via apopto-
sis [102, 103]. This pathway may be activated by stimuli of
temperature, toxicants, and oxidative stress. Four stages occur
in the process of apoptosis. The first one is cell reception of a
lethal stimulus, which is followed by activation of early sig-
naling molecules of caspase 8, P53, or C-myc in the second
Fig. 4 Vitrified-warmed MII
stage oocytes. Ultrastructure of
multivesicular bodies (a) and
lysosomes, sometimes associated
with vacuoles (b).MVB
multivesicular body, Ly lysosome,
m mitochondria, MV
mithocondria-vacuoles
complexes, V vacuoles (modified
from: [67] Nottola et al., 2009 (a)
and [69] Bianchi et al., 2014 (b))
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stage. These signals are relayed into central regulators (e.g.,
Bax and Bcl-2) at stage three, which results in life or death of
the cell. The final stage initiates effectors molecules of caspase
3 [94, 104]. Anchamparuthy et al. [105] demonstrated that
transcript levels of Fas, FasL, Bax, and Bcl-2 increased post-
vitrification and GV maturation. Our recent study evaluated
the effects of vitrification on expression patterns of apoptosis-
related (Bax, Bcl-2), DNMT1, and stress-related genes (Sod1,
HSP70) of GV human oocytes retrieved from ICSI and ma-
tured by IVM technology [106]. Our results showed that the
expression level of DNMT1 was reduced in the vIVM group,
which may cause alteration in the patterns of DNA methyla-
tion, resulting in disruption of gene expression, genomic im-
printing, and genome stabilization, leading to cell death. In
this study, although the expression of apoptosis-related genes
significantly upregulated in vitrified and fresh oocytes, the
pro-apoptotic (Bax) mRNA level increased more than 14
times in vitrified oocytes. The ratio of Bcl-2 and Bax may
be useful for measuring the oocytes tendency towards either
survival or apoptosis. The results also showed that the ratio of
pro-apoptotic to anti-apoptotic mRNA, was upregulated 4.3
times in vitrified oocytes [106]. This can, probably, justify the
partial recovery capacity of oocytes after vitrification and
IVM.
Conclusions
Immature oocyte IVM is a promising treatment of several
types of infertility, without recourse to ovarian stimulation,
especially for young women [107]. Cryopreservation of oo-
cytes has gained importance with increased demand to pre-
serve oocytes for future use. Vitrification is now routinely
used in ARTs, also in association to IVM programs [47, 48].
However, alterations found on the oocyte ultrastructure by
means of TEM, as reduction of the microvillar layer,
vacuolization, increase of MV complexes and alteration of
M-SER aggregates, could affect the oocyte mRNA content,
as seen by an increase of stress and apoptosis related gene
expression after vitrification/warming in human immature oo-
cytes. Therefore, low maturation rates of immature oocytes
vitrified prior to IVM could be explained by the observed
alterations in their ultrastructure and gene expression profile.
The use of vitrified immature human oocytes should be
reconsidered for fertility preservation in cases of low or poor
ovarian reserve, PCO/PCOS and cancer patients, although
more studies have to be done to confirm these findings, espe-
cially to clarify the best maturation stage for vitrification.
Finally, it is worth noting that, despite the presence of nu-
merous and different organelle alterations—from a slight to a
Fig. 5 Voluminous aggregates
between mitochondria and
elements of smooth endoplasmic
reticulum are seen in fresh (a) and
vitrified-warmed MII stage
oocytes (b). Immature M-SER
aggregates can be also found after
vitrification (c). M-SER
mitochondria-smooth
endoplasmic reticulum
aggregates, V vacuole (modified
from: [72] Coticchio et al., 2010
(a); [67] Nottola et al., 2009
(b, c))
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moderate extent—in a high number of oocytes subjected to
IVM and/or vitrification, these oocytes quite often survive
these procedures and even undergo maturation and fertiliza-
tion, with a fairly good success. At this regard, we speculate
that some of the above described ultrastructural alterations
may be transient, and a partial or total recovery may occur at
fertilization or during early embryo development, due to or-
ganelle remodeling and membrane recycling [108].We cannot
exclude, however, that these alterations may persist as latent in
these early stages, being responsible of defects that become
visible only later, during fetal and post-natal life.
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